|
|||||
|
|
Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer |
|
| Authors: | Pieter H Anborgh Danny J Lee Pieter F Stam Ann F Chambers |
| Institution: | 1. London Regional Cancer Program, London, Ontario, Canada;2. Departments of Oncology and of Pathology, University of Western Ontario, London, Ontario, Canada |
| Abstract: | Objective: Effective targeted therapies for patients with triple-negative breast cancer (TNBC) present an unmet clinical need. There is evidence that TNBCs often have increased expression of the epidermal growth factor receptor (EGFR) and of osteopontin (OPN). OPN-mediated signaling can activate EGFR-dependent signaling pathways. Here, we assessed OPN as a potential predictive biomarker for response to anti-EGFR therapy in TNBC. Research design and methods: Using two different TNBC cell lines, MDA-MB-468 and MDA-MB-231, we investigated the impact of stable expression of OPN on efficacy of the EGFR inhibitor erlotinib in vitro. Results: We observed that breast cancer cells engineered to overexpress OPN are more sensitive to growth inhibition by erlotinib than control cells. The level of response was related to the level of OPN expression, possibly due to increased phosphorylation status of EGFR Tyr1068. Conclusions: These results indicate that OPN expression levels are related to sensitivity of TNBC cells to growth inhibition by erlotinib. OPN thus is a promising predictive biomarker for anti-EGFR therapy in breast cancer. |
| Keywords: | Osteopontin anti-EGFR therapy breast cancer erlotinib predictive biomarker |